Ivonescimab Plus Chemotherapy versus Bevacizumab Plus Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After EGFR-TKI Failure: A Two-Center Retrospective Real-World Propensity Score-Matched Study
Jianxi Zhou, Yinghao Wang, Kang Wen, Chun Huang, Dingzhi Huang, Tingting Qin, Mengjie Li, Yudong Su, Yunchuan Sun, Peng Chen · 2026
Read Ivonescimab Plus Chemotherapy versus Bevacizumab Plus Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After EGFR-TKI Failure: A Two-Center Retrospective Real-World Propensity Score-Matched Study by Jianxi Zhou, Yinghao Wang, Kang Wen, Chun Huang, Dingzhi Huang, Tingting Qin, Mengjie Li, Yudong Su, Yunchuan Sun, Peng Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13546669.txt.
Description
Jianxi Zhou and co-authors compare two drug combinations for lung cancer that has outgrown its first targeted therapy, in a 2026 real-world study. The patients' tumors carried EGFR mutations and had failed EGFR-blocking pills. One group got ivonescimab, a dual-action antibody, plus chemotherapy; the other got bevacizumab plus chemotherapy.
From 390 patients at two centers, matching produced 120 balanced pairs. The ivonescimab group went a median 7.6 months before progression against 5.9, and lived 18.0 against 15.1 months. Tumors shrank in 45 percent versus 28 percent, and disease control was higher too. Side effects were comparable. Patients whose tumors scored high on a PD-L1 test gained most. The authors call for a prospective trial to confirm.
Catalog record
| CREATOR | Jianxi Zhou, Yinghao Wang, Kang Wen, Chun Huang, Dingzhi Huang, Tingting Qin, Mengjie Li, Yudong Su, Yunchuan Sun, Peng Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |